WallStSmart

Edwards Lifesciences Corp (EW)vs908 Devices Inc (MASS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 10806% more annual revenue ($6.30B vs $57.80M). EW leads profitability with a 17.4% profit margin vs -62.4%. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

MASS

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: 0.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.7%)

Margin of Safety

+68.7%

Fair Value

$253.29

Current Price

$85.96

$167.33 discount

UndervaluedFair: $253.29Overvalued
MASSUndervalued (+51.5%)

Margin of Safety

+51.5%

Fair Value

$13.60

Current Price

$8.66

$4.94 discount

UndervaluedFair: $13.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW4 strengths · Avg: 9.5/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

MASS2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.054/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

MASS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$299.86M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-26.8%2/10

ROE of -26.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : MASS

The strongest argument for MASS centers on Debt/Equity, Price/Book. Revenue growth of 13.6% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Bear Case : MASS

The primary concerns for MASS are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

EW profiles as a growth stock while MASS is a turnaround play — different risk/reward profiles.

EW carries more volatility with a beta of 0.87 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

MASS generates stronger free cash flow (1M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 30/100), backed by strong 17.4% margins and 16.7% revenue growth. MASS offers better value entry with a 51.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

908 Devices Inc

HEALTHCARE · MEDICAL DEVICES · USA

908 Devices Inc. develops and sells measuring devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and Asia Pacific. The company is headquartered in Boston, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?